All-trans retinoic acid is named as an intervention in 6 current clinical trials in our China and Ireland registers. 3 are recruiting patients now. The most common phase is Phase 2. The sponsor with the most trials is Peking University People's Hospital (2). The most-studied condition is Persistent Isolated Chemotherapy-Induced Thrombocytopenia.
| Study | Phase | Status | Lead sponsor | Registers |
|---|---|---|---|---|
|
Treatment Study for Children and Adolescents With Acute Promyelocytic Leukemia
NCT04793919 · Acute Promyelocytic Leukemia
|
Phase 2 | Recruiting | Associazione Italiana Ematologia Oncologia Pediatrica | Ireland |
|
Romiplostim N01 Plus ATRA for Persistent Isolated Chemotherapy-Induced Thrombocytopenia After Complete Remission of Gastrointestinal Solid Tumors
NCT07586813 · ClinicalTrials.gov ↗ · Persistent Isolated Chemotherapy-Induced Thrombocytopenia, Chemotherapy-Induced Thrombocytopenia, Gastrointestinal Neoplasms
|
Phase 2 | Recruiting | Peking University People's Hospital | China |
|
Romiplostim N01 Plus ATRA for Persistent Isolated Chemotherapy-Induced Thrombocytopenia After Complete Remission of Gynecologic, Breast, or Lung Solid Tumors
NCT07586826 · ClinicalTrials.gov ↗ · Persistent Isolated Chemotherapy-Induced Thrombocytopenia, Chemotherapy-Induced Thrombocytopenia, Gynecologic Cancers
|
Phase 2 | Recruiting | Peking University People's Hospital | China |
|
ARTA-based Chemo-free Bridging/Maintenance Therapy in CAR-T Treatment for High-Risk R/R B-NHL Ineligible for HDCT and ASCT
NCT06646666 · ClinicalTrials.gov ↗ · B-cell Non Hodgkin Lymphoma
|
Phase 2 | Not yet open | Ruijin Hospital | China |
|
Efficacy and Safety of ATO Plus ATRA in Nucleophosmin-1 Mutated Acute Myeloid Leukemia
NCT03031249 · ClinicalTrials.gov ↗ · AML
|
Phase 1/2 | By invitation | Institute of Hematology & Blood Diseases Hospital, China | China |
|
Venetoclax Combined With ATRA and ATO in Hyperleukocytic Acute Promyelocytic Leukemia
NCT07187505 · ClinicalTrials.gov ↗ · Acute Promyelocytic Leukemia (APL)
|
Not applicable | Active, closed | Anhui Medical University | China |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
| Lead sponsor | Trials |
|---|---|
| Peking University People's Hospital | 2 |
| Associazione Italiana Ematologia Oncologia Pediatrica | 1 |
| Ruijin Hospital | 1 |
| Anhui Medical University | 1 |
| Institute of Hematology & Blood Diseases Hospital, China | 1 |
| Register | Trials | Recruiting |
|---|---|---|
| Clinical trials in China | 5 | 2 |
| Clinical trials in Ireland | 1 | 1 |
A trial with sites in more than one country appears in each of those registers.
6 current trials in our China and Ireland registers name All-trans retinoic acid as a drug or biological intervention, as of the registry sync on 25 September 2026. Completed and withdrawn studies are not counted.
Yes. 3 of the 6 trials are recruiting: 2 with sites in China and 1 with sites in Ireland. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
Peking University People's Hospital (2), Associazione Italiana Ematologia Oncologia Pediatrica (1), Ruijin Hospital (1) and Anhui Medical University (1), among 5 lead sponsors in total. The number in brackets is how many trials each organisation leads.
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how All-trans retinoic acid works or whether it is effective, and it is not medical advice.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how All-trans retinoic acid works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists All-trans retinoic acid (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 25 Sep 2026.